- Treatment
Landscape- ABSSSI
Treatment
Burden- ABSSSI
Treatment
Challenges- About
KIMYRSA®- What is
KIMYRSA®?- Mechanisms
of Action- PK Profile
- In Vitro
Results by Pathogen- Clinical
Studies- Clinical Study Information
- SOLO Studies
- Real-World
Experience- Real-World Studies
- Real Patient Results
- Single-Dose
Administration- Resources
and SupportBack To Work
Help them escape the limits of multidose IV therapy
Treat ABSSSI, including cellulitis, abscesses, and wound infections, with KIMYRSA®— a single-dose
1-hour infusion therapy that helps patients avoid the obstacles of multidose IV treatments.1,2*Back To everyday
Help them escape the limits of multidose IV therapy
Treat ABSSSI, including cellulitis, abscesses, and wound infections, with KIMYRSA®— a single-dose
1-hour infusion therapy that helps patients avoid the obstacles of multidose IV treatments.1,2*A single infusion ensures adherence to a full course of therapy1
Proven reductions in hospital admissions, length of stay, and readmissions1,3-9
Find out how to get KIMYRSA® for your patients
References: 1. Kimyrsa. Package insert. Melinta Therapeutics; 2021. 2. Jin J, Sklar GE, Min Sen Oh V, Chuen Li S. Factors affecting therapeutic compliance: a review from the patient's perspective. Ther Clin Risk Manag. 2008;4(1):269-286. doi:10.2147/tcrm.s1458 3. Redell M, Moeck G, Lucasti C, et al. A real-world patient registry for oritavancin demonstrates efficacy and safety consistent with the phase 3 SOLO program. Open Forum Infect Dis. 2018;5(6):ofy051. doi:10.1093/ ofid/ofy051 4. Lodise T, Redell M, Armstrong S, Sulham K, Corey G. Efficacy and safety of oritavancin relative to vancomycin for patients with acute bacterial skin and skin structure infections (ABSSSI) in the outpatient setting: results from the SOLO clinical trials. Open Forum Infect Dis. 2017;4(1):ofw274. doi:10.1093/ofid/ofw274 5. Helton B, MacWhinnie A, Minor SB, et al.Early directed oritavancin therapy in the emergency department may lead to hospital avoidance compared to standard treatment for acute bacterial skin and skin structure infections: a real-world retrospective analysis. Drugs Real World Outcomes. 2020;7(suppl 1):20-29. doi:10.1007/s40801-020-00201-y 6. Whittaker C, Lodise TP, Nhan E, Reilly J. Expediting discharge in hospitalized, adult patients with skin and soft tissue infections who received empiric vancomycin therapy with oritavancin: description of findings from an institutional pathway. Drugs Real World Outcomes. 2020;7(suppl 1):30-35. doi:10.1007/s40801-020-00196-6 7. Anastasio PJ, Wolthoff P, Galli A, Fan W. Single-dose oritavancin compared to standard of care IV antibiotics for acute bacterial skin and skin structure infection in the outpatient setting: a retrospective real-world study. Infect Dis Ther. 2017;6(1):115-128. doi:10.1007/s40121-016- 0145-7 8. Turner E, Estrada S, Galli A, Armstrong S, Delaportas D. Treatment of acute bacterial skin and skin structure infections (ABSSSI) in the outpatient setting: clinical and economic outcomes from a real-world multi-center study of oritavancin. Poster presented at: ASHP Conference for Pharmacy Leaders; October 17-18, 2016; Chicago, IL. 9. Estrada S, Lodise TP, Tillotson GS, et al. The real world economic and clinical management of adult patients with skin and soft tissue infections (SSTIs) with oritavancin: data from two multicenter observational cohort studies. Drugs Real World Outcomes. 2020;7(suppl 1):6-12. doi:10.1007/s40801-020-00199-3
*INDICATION AND USAGE
- Both KIMYRSA® and ORBACTIV® are oritavancin products that are indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused or suspected to be caused by susceptible isolates of the following gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible [MSSA] and methicillin-resistant [MRSA] isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus anginosus group (includes S. anginosus, S. intermedius, and S. constellatus), and Enterococcus faecalis (vancomycin-susceptible isolates only).
- To reduce the development of drug-resistant bacteria and maintain the effectiveness of oritavancin and other antibacterial drugs, oritavancin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.
- KIMYRSA® and ORBACTIV® are not approved for combination use and have differences in dose strength, duration of infusion, and preparation instructions, including reconstitution and dilution instructions and compatible diluents. Please see the full Prescribing Information for each product.
IMPORTANT SAFETY INFORMATION
Contraindications
- Use of intravenous unfractionated heparin sodium is contraindicated for 120 hours (5 days) after oritavancin administration because the activated partial thromboplastin time (aPTT) test results may remain falsely elevated for approximately 120 hours (5 days) after oritavancin administration.
- Oritavancin products are contraindicated in patients with known hypersensitivity to oritavancin.
Warnings and Precautions
- Coagulation test interference: Oritavancin has been shown to artificially prolong aPTT for up to 120 hours, and may prolong PT and INR for up to 12 hours and ACT for up to 24 hours. Oritavancin has also been shown to elevate D-dimer concentrations up to 72 hours. For patients who require aPTT monitoring within 120 hours of oritavancin dosing, consider a non-phospholipid dependent coagulation test such as a Factor Xa (chromogenic) assay or an alternative anticoagulant not requiring aPTT.
- Serious hypersensitivity reactions, including anaphylaxis, have been reported with the use of oritavancin products. Discontinue infusion if signs of acute hypersensitivity occur. Closely monitor patients with known hypersensitivity to glycopeptides.
- Infusion related reactions: Infusion reactions characterized by chest pain, back pain, chills and tremor have been observed with the use of oritavancin products, including after the administration of more than one dose of oritavancin during a single course of therapy. Stopping or slowing the infusion may result in cessation of these reactions.
- Clostridioides difficile-associated diarrhea: Evaluate patients if diarrhea occurs.
- Concomitant warfarin use: Oritavancin has been shown to artificially prolong PT/INR for up to 12 hours. Patients should be monitored for bleeding if concomitantly receiving oritavancin products and warfarin.
- Osteomyelitis: Institute appropriate alternate antibacterial therapy in patients with confirmed or suspected osteomyelitis.
- Prescribing oritavancin products in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of development of drug-resistant bacteria.
Adverse Reactions
- The most common adverse reactions (≥3%) in patients treated with oritavancin products were headache, nausea, vomiting, limb and subcutaneous abscesses, and diarrhea. The adverse reactions occurring in ≥2 patients receiving KIMYRSA® were hypersensitivity, pruritus, chills and pyrexia.
Please see Full Prescribing Information for ORBACTIV®.
Please see Full Prescribing Information for KIMYRSA®.
SEE MORE*INDICATION AND USAGE
Both KIMYRSA® and ORBACTIV® are oritavancin products that are indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused or suspected to be
IMPORTANT SAFETY INFORMATION
ContraindicationsUse of intravenous unfractionated heparin sodium is contraindicated for 120 hours (5 days) after oritavancin
- Real Patient Results
- SOLO Studies
- Mechanisms
- ABSSSI
- ABSSSI